This company develops advanced genome editing technology characterized by high precision, efficiency, and safety for therapeutic applications. They utilize an LLM-powered, multi-agent platform to automate genetic intervention discovery, aiming to deliver advantageous genetic variants to the general population. The core offering focuses on proactive aging prevention and performance enhancement through precise genomic solutions.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
CRISPR gene editing, while promising, can suffer from off-target effects and limited efficiency in achieving precise edits, raising safety concerns and hindering therapeutic applications. Existing methods lack the ability to fine-tune the editing process for optimal precision, efficacy, and safety.
Solution
This startup offers Safeguard, a patented genome editing technology designed to enhance CRISPR's performance. Safeguard allows for fine-tuning of the genome editing process, optimizing for precision, efficacy, and safety. The technology significantly reduces off-target effects, increases homology-directed repair (HDR) efficiency, and minimizes adverse reactions such as p53 activation, cytotoxicity, and DNA damage. By improving the accuracy and control of gene editing, Safeguard enables the development of safer and more effective targeted therapies.
Target Audience
The primary customers are researchers and pharmaceutical companies developing gene therapies for genetic diseases, cancer, and age-related conditions.
Features
- Safeguard sgRNA technology enhances the safety and precision of CRISPR gene editing.
- Achieves up to 3000x improvement in precision, reducing off-target effects.
- Increases HDR efficiency by up to 7x, improving the success rate of precise edits.
- Enhances safety by up to 100x, minimizing adverse effects like p53 activation and cytotoxicity.
- Enables fine-tuning of Cas activity to optimize HDR efficiency.